Gleevec and Evista drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gleevec (imatinib mesylate) and Evista (raloxifene hydrochloride). Common drug interactions include infection among females and abnormal weight gain among males.

The phase IV clinical study analyzes what interactions people have when they take Gleevec and Evista. It is created by eHealthMe based on reports of 39 people who take the same drugs from the FDA, and is updated regularly.

What is Gleevec?

Gleevec has active ingredients of imatinib mesylate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 35,415 Gleevec users. Check the latest studies of Gleevec.

What is Evista?

Evista has active ingredients of raloxifene hydrochloride. It is often used in osteoporosis. eHealthMe is studying from 25,891 Evista users. Check the latest studies of Evista.

On Jul, 27, 2026

39 people who take Gleevec and Evista together, and have interactions are studied.

What are the common drug interactions of Gleevec and Evista, by gender? *:

female:

Infection
Lymphoma (cancer that begins in immune system cells)
Mastocytosis (an excessive number of apparently normal mast cells in the skin and, occasionally, in other organs)
Metastasis (spreadable cancer to other organ from origin)
Mouth ulceration (mouth ulcers)
Nasal septum deviation (deviated nasal septum)
Oral disorder (mouth disease)
Oral pain
Osteoarthritis (a joint disease caused by cartilage loss in a joint)
Osteomyelitis (infection of bone)

male:

Abnormal weight gain
Death

What are the common drug interactions of Gleevec and Evista, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Platelet aggregation
Rash
Subdural haemorrhage (bleeding between the skull and the surface of the brain)
Haematocrit decreased
Headache (pain in head)

50-59:

Brain oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain)
Subdural haematoma (blood collects between the skull and the surface of the brain)
Areflexia (absence of a reflex)
Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
Disorientation (disability in which the senses of time, direction, and recognition of people and places)
Headache (pain in head)
Mental impairment (a condition affecting the body, perhaps through sight or hearing loss, a mobility difficulty or a health condition)
Mydriasis (a dilation of the pupil)
Nausea (feeling of having an urge to vomit)
Somnolence (a state of near-sleep, a strong desire for sleep)

60+:

Astrocytoma (tumour of the brain that originate in a particular kind of glial-cells)
Basedow's disease (autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones)
Mastocytosis (an excessive number of apparently normal mast cells in the skin and, occasionally, in other organs)
Metastasis (spreadable cancer to other organ from origin)
Mouth ulceration (mouth ulcers)
Nasal septum deviation (deviated nasal septum)
Oral disorder (mouth disease)
Oral pain
Osteoarthritis (a joint disease caused by cartilage loss in a joint)
Osteomyelitis (infection of bone)

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 14 people, 35.90%
Urticaria Pigmentosa (skin disease that produces patches of darker skin (lesions) and very bad itching): 13 people, 33.33%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 10 people, 25.64%
Acute Myeloid Leukaemia (In Remission): 5 people, 12.82%
Gastrointestinal Stromal Tumor: 2 people, 5.13%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Gleevec and Evista?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously